Literature DB >> 6379060

Plasmid-mediated resistance in multiply resistant Haemophilus influenzae type b causing meningitis: molecular characterization of one strain and review of the literature.

P M Mendelman, C A Doroshow, S L Gandy, V Syriopoulou, C P Weigen, A L Smith.   

Abstract

The increasing prevalence of infections due to ampicillin-resistant strains of Haemophilus influenzae type b requires that suspected H. influenzae meningitis in children be initially treated with both ampicillin and chloramphenicol. Previously, the recognition of strains resistant to chloramphenicol but susceptible to ampicillin supported combination chemotherapy. In this study one case of meningitis due to a strain of H. influenzae resistant to ampicillin, chloramphenicol, and tetracycline was analyzed. The patient involved received intravenous trimethoprim-sulfamethoxazole, but putative resistance to this combination prompted the additional administration of intravenous moxalactam. The resistance of this organism was mediated by a conjugative 43-megadalton R plasmid; the determinants of ampicillin and chloramphenicol resistance were transferred as a single unit. However, not all of the multiply resistant transconjugants contained a detectable plasmid; DNA homology studies with R plasmids of H. influenzae confirmed that these extrachromosomal DNA sequences were associated with chromosomal DNA and that an extrachromosomal location was rare.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379060     DOI: 10.1093/infdis/150.1.30

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  Haemophilus influenzae: antibiotic susceptibility.

Authors:  C A Needham
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

2.  Comparative activities of LY 164846 and other orally administered beta-lactam antibiotics against Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; A W Howell
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

3.  Disk diffusion interpretive criteria for extended-spectrum cephalosporins with Haemophilus influenzae.

Authors:  J H Jorgensen; L A Maher; J S Redding
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

4.  Failure to detect ampicillin-resistant, non-beta-lactamase-producing Haemophilus influenzae by standard disk susceptibility testing.

Authors:  P M Mendelman; D O Chaffin; C Clausen; T L Stull; C Needham; J D Williams; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

5.  Surveillance study of resistance in Haemophilus species in Greece.

Authors:  K Kanellakopoulou; H Giamarellou; A Avlamis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

Review 6.  Mechanisms of beta-lactam resistance in Haemophilus influenzae.

Authors:  L Gutmann; R Williamson; E Collatz; J F Acar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

Review 7.  Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy.

Authors:  R de Groot; G Dzoljic-Danilovic; B van Klingeren; W H Goessens; H J Neyens
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

8.  In vitro activity of orally administered antimicrobial agents against Haemophilus influenzae recovered from children monitored longitudinally in a group day-care center.

Authors:  M J George; B Kitch; F W Henderson; P H Gilligan
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

10.  Haemophilus influenzae type b meningitis resistant to ampicillin and chloramphenicol.

Authors:  H Guiscafré; F Solórzano; O Delgado; O Muñoz
Journal:  Arch Dis Child       Date:  1986-07       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.